220 related articles for article (PubMed ID: 18704226)
1. Protein kinase CK2 as a druggable target.
Sarno S; Pinna LA
Mol Biosyst; 2008 Sep; 4(9):889-94. PubMed ID: 18704226
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase CK2: a newcomer in the 'druggable kinome'.
Pagano MA; Cesaro L; Meggio F; Pinna LA
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1303-6. PubMed ID: 17073807
[TBL] [Abstract][Full Text] [Related]
3. Assessment of CK2 constitutive activity in cancer cells.
Ruzzene M; Di Maira G; Tosoni K; Pinna LA
Methods Enzymol; 2010; 484():495-514. PubMed ID: 21036247
[TBL] [Abstract][Full Text] [Related]
4. Casein Kinase II: an attractive target for anti-cancer drug design.
Hanif IM; Hanif IM; Shazib MA; Ahmad KA; Pervaiz S
Int J Biochem Cell Biol; 2010 Oct; 42(10):1602-5. PubMed ID: 20558317
[TBL] [Abstract][Full Text] [Related]
5. Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application.
Cozza G; Bonvini P; Zorzi E; Poletto G; Pagano MA; Sarno S; Donella-Deana A; Zagotto G; Rosolen A; Pinna LA; Meggio F; Moro S
J Med Chem; 2006 Apr; 49(8):2363-6. PubMed ID: 16610779
[TBL] [Abstract][Full Text] [Related]
6. New protein kinase CK2 inhibitors: jumping out of the catalytic box.
Prudent R; Cochet C
Chem Biol; 2009 Feb; 16(2):112-20. PubMed ID: 19246001
[TBL] [Abstract][Full Text] [Related]
7. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.
Pagano MA; Andrzejewska M; Ruzzene M; Sarno S; Cesaro L; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Pinna LA
J Med Chem; 2004 Dec; 47(25):6239-47. PubMed ID: 15566294
[TBL] [Abstract][Full Text] [Related]
8. [Inhibitory effect and its kinetic analysis of baicalein on recombinant human protein kinase CK2 holoenzyme].
Lin XC; Liu XG; Chen XW; Chen WZ; Liang NC
Ai Zheng; 2004 Aug; 23(8):874-8. PubMed ID: 15301706
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level.
Di Maira G; Brustolon F; Bertacchini J; Tosoni K; Marmiroli S; Pinna LA; Ruzzene M
Oncogene; 2007 Oct; 26(48):6915-26. PubMed ID: 17486073
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2.
Golub AG; Yakovenko OY; Bdzhola VG; Sapelkin VM; Zien P; Yarmoluk SM
J Med Chem; 2006 Nov; 49(22):6443-50. PubMed ID: 17064064
[TBL] [Abstract][Full Text] [Related]
11. ATP site-directed inhibitors of protein kinase CK2: an update.
Sarno S; Papinutto E; Franchin C; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Orzeszko A; Zanotti G; Battistutta R; Pinna LA
Curr Top Med Chem; 2011; 11(11):1340-51. PubMed ID: 21513497
[TBL] [Abstract][Full Text] [Related]
12. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
[TBL] [Abstract][Full Text] [Related]
13. Cellular regulators of protein kinase CK2.
Montenarh M
Cell Tissue Res; 2010 Nov; 342(2):139-46. PubMed ID: 20976471
[TBL] [Abstract][Full Text] [Related]
14. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.
Hou Z; Nakanishi I; Kinoshita T; Takei Y; Yasue M; Misu R; Suzuki Y; Nakamura S; Kure T; Ohno H; Murata K; Kitaura K; Hirasawa A; Tsujimoto G; Oishi S; Fujii N
J Med Chem; 2012 Mar; 55(6):2899-903. PubMed ID: 22339433
[TBL] [Abstract][Full Text] [Related]
16. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2.
Pagano MA; Meggio F; Ruzzene M; Andrzejewska M; Kazimierczuk Z; Pinna LA
Biochem Biophys Res Commun; 2004 Sep; 321(4):1040-4. PubMed ID: 15358133
[TBL] [Abstract][Full Text] [Related]
17. The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules.
Raaf J; Brunstein E; Issinger OG; Niefind K
Chem Biol; 2008 Feb; 15(2):111-7. PubMed ID: 18291315
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
Sarno S; de Moliner E; Ruzzene M; Pagano MA; Battistutta R; Bain J; Fabbro D; Schoepfer J; Elliott M; Furet P; Meggio F; Zanotti G; Pinna LA
Biochem J; 2003 Sep; 374(Pt 3):639-46. PubMed ID: 12816539
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study.
Meggio F; Pagano MA; Moro S; Zagotto G; Ruzzene M; Sarno S; Cozza G; Bain J; Elliott M; Deana AD; Brunati AM; Pinna LA
Biochemistry; 2004 Oct; 43(40):12931-6. PubMed ID: 15461466
[TBL] [Abstract][Full Text] [Related]
20. Discrimination between the activity of protein kinase CK2 holoenzyme and its catalytic subunits.
Salvi M; Sarno S; Marin O; Meggio F; Itarte E; Pinna LA
FEBS Lett; 2006 Jul; 580(16):3948-52. PubMed ID: 16806200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
